Diagnostic Delays in Spasmodic Dysphonia: A Call for Clinician Education

Similar documents
THE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN

A Separation of Innate and Learned Vocal Behaviors Defines the Symptomatology of Spasmodic Dysphonia

Spasmodic dysphonia Symptoms

Parkinson's Disease Center and Movement Disorders Clinic

Voice Handicap Index and Voice-related Quality of Life after Botulinum Toxin Injection for Spasmodic Dysphonia Patients

Parkinson's Disease Center and Movement Disorders Clinic

The treatment of adductor spasmodic dysphonia. Information for patients

Source: *Dystonia facts medically edited by: Charles Patrick Davis, MD, PhD

Assessment of health-related quality of life (HRQoL) in patients with spasmodic dysphonia

Patterns in the Evaluation of Hoarseness: Time to Presentation, Laryngeal Visualization, and Diagnostic Accuracy

Understanding Parkinson s Disease Important information for you and your loved ones

Hoarseness. Evidence-based Key points for Approach

ORIGINAL CONTRIBUTION

Parkinson's Disease Center and Movement Disorders Clinic

Disclosures. Roadmap of Talk 2/5/2018. Treatment Options for Vocal Tremor. Voice Evaluation Tasks of Interest

Dystonia: Title. A real pain in the neck. in All the Wrong Places

Safety and Efficacy of Multiuse Botulinum Toxin Vials for Intralaryngeal Injection

Dystonias. How are the dystonias classified? One way of classifying the dystonias is according to the parts of the body they affect:

Dystonia Clinic Patient Information Leaflet

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Professor Tim Anderson

Management of Hoarseness in Primary Care

Surgical Treatment. Clinical Course of Laryngeal Granuloma Without INTRODUCTION

This guide describes some of the important facts about Neurobloc that you need to be aware of, however, it does not replace the advice given to you

Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia

DMRF CANADA THE DYSTONIA SURVEY REPORT

HOARSENESS. Prevention and types of treatment

Hoarseness and Laryngopharyngeal Reflux A Survey of Primary Care Physician Practice Patterns

Journal of Anesthesia & Pain Medicine

BOTULINUM TOXIN POLICY TO INCLUDE:

Quantitative Assessment of Botulinum Toxin Treatment in 43 Patients with Head Tremor

Professor Tim Anderson

Dystonia. The condition can vary from very mild to severe. Dystonia may get worse over time or it may stay the same or get better.

Botulinum Toxin Injections Patient Information Leaflet

Table of Contents. Preface... xi. Part I: Introduction to Movement Disorders

Pallidal Deep Brain Stimulation

Disorders of language and speech. Samuel Komoly MD PhD DHAS Professor and Chairman Department of Neurology

The Paediatric Voice Clinic

Practice patterns regarding noninvasive rhinosinusitis in the immunosuppressed patient population

National Institute for Health and Clinical Excellence

Longitudinal Effects of Botulinum Toxin Injections on Voice-Related Quality of Life (V-RQOL) for Patients with Adductory Spasmodic Dysphonia

Adductor focal laryngeal Dystonia: correlation between clinicians ratings and subjects perception of Dysphonia

Botox. Botox (onabotulinum toxin A) Description

NIH Public Access Author Manuscript Parkinsonism Relat Disord. Author manuscript; available in PMC 2009 August 1.

Neurological disorders. Dystonia Search date September 2013 Ailsa Snaith and Derick Wade ...

Jae Wook Kim, Jae Hong Park, Ki Nam Park, and Seung Won Lee. Correspondence should be addressed to Seung Won Lee;

GENETICS AND TREATMENT OF DYSTONIA

Hubert H. Fernandez, MD

Pearce, Catharine. Downloaded 22-Oct :14:

The effect of anti-reflux treatment on subjective voice measurements of patients with laryngopharyngeal reflux

Patient Group Input Submissions

Research Article Postthyroidectomy Throat Pain and Swallowing: Do Proton Pump Inhibitors Make a Difference?

Missouri Guidelines for the Use of Controlled Substances for the Treatment of Pain

Diffusion of aniline blue injected into the thyroarytenoid muscle as a proxy for botulinum toxin injection: an experimental study in cadaver larynges

Clare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct)

Cochlear Implant PROGRAM OVERVIEW

MYOBLOC and Cervical Dystonia A Patient s Guide

Movement Disorders- Parkinson s Disease. Fahed Saada, MD March 8 th, th Family Medicine Refresher Course St.

A Clicking Larynx: Diagnostic and Therapeutic Challenges

Sunshine Act Disclosure

Understanding Dystonia

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.

Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia

Public Policy Agenda 2016

CEDAC FINAL RECOMMENDATION

Moving fast or moving slow: an overview of Movement Disorders

Isolated vocal tremor as a focal phenotype of essential tremor: a retrospective case review

Scottish Medicines Consortium

DYSTONIA. Mysi05/Shutterstock

(2014) 99 (10) ISSN

Thought Field Therapy and Pain Robert Pasahow, PhD Diplomate, American Board of Medical Psychologists Director, Affiliates in Psychotherapy

Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)

Referral and pathways for surgically managed Carpal Tunnel Syndrome patients: guidelines and current practice

Chorus Study Guide Unit 1: Know Thy Voice

Opioids in the Management of Chronic Pain: An Overview

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

DBSA Survey Center Less Common Medication Side Effects Survey

Surgery or Botulinum Toxin for Adductor Spasmodic Dysphonia: A Comparative Study

Assessment of health related quality of life in patients with hemifacial spasm

FOR PARKINSON S DISEASE XADAGO NEXT?

Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm

Hoarseness Evaluation: A Transatlantic Survey Of Laryngeal Experts

Clinical practice guideline: Hoarseness (Dysphonia)

Clinical Policy: Voice Therapy Reference Number: CP.MP.HN 134

New treatment possibilities of laryngeal dystonia and related disorders.

DEEP BRAIN STIMULATION

Hemifacial spasm. Parkinson's Disease Center and Movement Disorders Clinic

1. On contacting a chiropractic clinic, patients seeking care for acute neck pain are offered an appointment within three working days.

HYPERTHYROIDISM IN CATS

Past, Present and Future of Spasmodic Dysphonia and the use of Botulinum toxin therapy

SURGERY FOR PEDIATRIC SUBGLOTTIC STENOSIS: DISEASE-SPECIFIC OUTCOMES

Your Voice Can Get Old, Too

2/18/ yo man with history of mild developmental delay and chorea of unclear etiology, with new complaints of speech difficulty

Test User got 22 of 22 possible points on the Risk Reduction Strategies for ER/LA Opioids Post-Test. Total score: 100 %

Survey of practices employed by neurologists for the definition and management of secondary nonresponse to botulinum toxin in cervical dystonia

PATIENTS WITH MULTIPLE SCLEROSIS

ORIGINAL ARTICLE. areas has accelerated during the past several decades.

New Jersey Department of Children and Families Policy Manual. Date: Chapter: A Health Services Subchapter: 1 Health Services

Back pain: Therapy for chronic low back pain Depression: features and screening opportunities in clinical practice

Transcription:

Diagnostic Delays in Spasmodic Dysphonia: A Call for Clinician Education Francis X. Creighton, Harvard University Edie Hapner, Emory University Adam Klein, Emory University Ami Rosen, Emory University Hyder Jinnah, Emory University Michael Johns, Emory University Journal Title: Journal of Voice Volume: Volume 29, Number 5 Publisher: Elsevier 2015-09-01, Pages 592-594 Type of Work: Article Post-print: After Peer Review Publisher DOI: 10.1016/j.jvoice.2013.10.022 Permanent URL: https://pid.emory.edu/ark:/25593/rr4gm Final published version: http://dx.doi.org/10.1016/j.jvoice.2013.10.022 Copyright information: 2015 The Voice Foundation. Accessed June 29, 2018 10:10 AM EDT

Diagnostic Delays in Spasmodic Dysphonia: A Call for Clinician Education Francis X. Creighton *, Edie Hapner, Adam Klein, Ami Rosen, Hyder A. Jinnah, and Michael M. Johns * Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts Department of Otolaryngology-Head and Neck Surgery, Emory Voice Center, Emory University School of Medicine, Atlanta, Georgia Department of Neurology, Emory University School of Medicine, Atlanta, Georgia Summary Purpose Spasmodic dysphonia (SD) is a rare but often debilitating disease. Due to lack of awareness among practitioners and lack of well-defined diagnostic criteria, it can be difficult for patients with SD to receive a diagnosis and subsequent treatment. There is currently no literature documenting the efficacy of the medical community in recognizing and diagnosing this disorder. We aimed to quantify the patients experiences with obtaining a diagnosis of SD. Methods One hundred seven consecutive patients with SD completed questionnaires about their experiences with SD. Patients were recruited either during outpatient laryngology visits or during participation in a National Institutes of Health funded study investigating SD. Results It took patients an average of 4.43 years (53.21 months) to be diagnosed with SD after first going to a physician with vocal symptoms. Patients had to see an average of 3.95 physicians to receive a diagnosis of SD. Patients (31.4%) had been prescribed medications other than botulinum toxin to treat their symptoms. Patients (30%) attempted alternative therapies for treatment of SD, such as chiropractor or dietary modification. Conclusions Despite advances in diagnostic modalities in medicine, the diagnosis of SD still remains elusive. Objective criteria for the diagnosis of SD and increased clinician education are warranted to address this diagnostic delay. Keywords HHS Public Access Author manuscript Published in final edited form as: J Voice. 2015 September ; 29(5): 592 594. doi:10.1016/j.jvoice.2013.10.022. Larynx; Voice; Spasmodic dysphonia; Diagnostic delay Address correspondence and reprint requests to Michael M. Johns, Emory Voice Center, Emory University, 550 Peachtree St. 9th Fl. Ste 4400, Atlanta, GA 30308. michael.johns2@emory.edu.

Creighton et al. Page 2 INTRODUCTION METHODS Spasmodic dysphonia (SD) is a form of focal dystonia that affects the laryngeal muscles. Patients experience involuntary and sustained contractions of the laryngeal muscles resulting in voice breaks and a strained or strangulated voice. Actions such as swallowing and singing are typically unaffected. 1 SD is a chronic, incurable, and disabling voice disorder. Current literature shows that SD typically presents in the 4th or 5th decade of life with a female predominance. 1,2 The etiology and pathogenesis of SD is unclear and current treatments provide only temporary relief of symptoms. SD is likely multifactorial in etiology, involving both genetic and environmental factors. A current limitation in our understanding of SD is that there is no systematic method for diagnosing or screening for the disease. Due to this limitation, many patients report complicated and drawn out processes to obtain a diagnosis, and worse still, many patients report being misdiagnosed with psychiatric and psychosomatic disorders to explain their symptoms. 1 This study aimed to shed better light on the process of being diagnosed with SD and assess the medical communities effectiveness in diagnosing this disorder. One hundred seven patients were enrolled in the study. Patients were recruited in one of the two ways. First, consecutive patients who were participating in the National Institutes of Health Dystonia Coalition Project 3: Spasmodic Dysphonia Diagnostic and Assessment Procedure at the Emory University Voice Center completed the study questionnaire about their experience with SD. Of the 107 patients, 26 patients were enrolled using this method. All other patients were enrolled during their regularly scheduled outpatient appointments at the Emory University Voice Center. Through this method, 81 consecutive patients answered the study questionnaire. The initial patient questionnaire used in this study focused on determining several factors regarding patients experiences. Patients were asked the length of time it took them to receive a diagnosis after initially seeing a doctor for their symptoms. Patients were also asked how many physicians they had to see before getting a diagnosis of SD and if any of those doctors were neurologists. Finally, patients were asked whether or not they had dystonia in other parts of their body, and if they did, what specific types. During the study, this questionnaire was revised to gather a wider range of information. In the revised questionnaire, patients were also asked at what age did they begin having symptoms and at what age were they ultimately diagnosed. Patients were also asked if they had been prescribed any medications other than botulinum toxin, as well as if they had tried any alternative therapies (ie, chiropractor, diet, and so forth) to treat their symptoms. Statistical analysis was performed using SPSS (IBM, Cambridge, MA, USA) software. Mean values for length of time to diagnosis, the number of physicians seen, and the average age of onset were calculated. The percentage of patients prescribed medications other than

Creighton et al. Page 3 RESULTS DISCUSSION Botox, who tried alternative therapies, and who saw a neurologist was determined. Finally, gender analysis was performed. All patients signed consent forms before participating in the study. All questionnaires and consents were approved by the Institutional Review Board of Emory University. Of the 107 patients enrolled, 80.4% were female and 19.6% were male. It took patients an average of 53.21 months or 4.43 years (σ = 79.4 months) after first seeing a physician for their symptoms to be ultimately diagnosed with SD. These patients saw an average of 3.95 (σ = 3.9 physicians) physicians before being diagnosed. Average age of symptom onset was 44.65 years (σ = 13.6 years). Only 33.6% of patients had seen a neurologist. Patients (31.4%) were prescribed a medication other than Botox to treat their symptoms. As seen in Figure 1, a total of 15.6% of patients were prescribed antianxiety medication and 9.4% were prescribed acid reflux medication. Thirty percent of patients tried alternative therapies to alleviate their symptoms. Figure 2 shows that 6.8% saw a chiropractor, whereas 3.4% tried to alter their diet. Patients (24.4%) reported having a dystonia in another part of their body with cervical dystonia, 14.1%, being the most common. Our study shows that there is a substantial delay in the diagnosis of SD. Patients reported an average of almost 4.5 years from the time they first sought treatment until ultimate diagnosis. This period is obviously too long. This delay is not only too long for patients, who struggle with the social and professional difficulties of SD symptoms, but from a larger public health perspective, this delay wastes health care resources. Patients reported seeing an average of almost four physicians while seeking a diagnosis, which wastes both health care resources as well as patients time. Although seeing multiple physicians is a waste of resources and money, more importantly, patients are often, over 30% of the time, exposed to medications unnecessarily. Although prescriptions such as acid reflux medications are likely benign, over 15% of patients were prescribed antianxiety medications, which carry serious medical side effects and addiction potential. To improve patient care, safety, and streamline the use of precious health care resources, we believe that greater education among clinicians on the signs and symptoms of SD is needed to improve the delays in diagnosis. Although data were not collected specifically looking into which type of physicians patients saw before obtaining a diagnosis from an otolaryngologist, it is likely that most of these patients saw their primary care physician at some point during their diagnostic journey. Therefore, education should not focus on otolaryngologists alone but also on primary care providers and internist to help facilitate triage toward appropriate providers. The remainder of the data from this study provides further information on the epidemiology of SD. Just over 80% of our patients were female, which is similar to the previous studies. 1 The average age of onset was 44.65 years, which was slightly younger than what most

Creighton et al. Page 4 CONCLUSIONS Acknowledgments References previous studies report. 1 3 There was a wide standard deviation (σ = 13.6 years) for the average age of onset and wide range in age of onset, from 9 to 70 years, which might explain the small differences seen from previous literature. Interestingly, the percentage of patients reporting a secondary dystonia other that SD was high, almost 25%. Most patients reported having cervical dystonia, 14.1%, whereas 2.6% reported having writer s cramp. These numbers are different from previous reports, which indicate that writer s cramp is the most common focal dystonia in patients with SD. 3 Although these differences are small, the important implication from this data is that clearly SD is related to other forms of dystonia. Although almost 25% of our patients reported having a second dystonia, the national prevalence has been reported anywhere from 0.280% to 0.03%, clearly indicating a relationship. 4,5 The information from this study can help inform clinicians in the diagnosis of SD. The epidemiologic information provides clinicians expected age ranges, average age of 44.65 years, and gender disparities, 80% female predominance, related to SD. Furthermore, the data show that multiple different medications patients have been prescribed inappropriately for SD symptoms, and, therefore, clinicians should think of SD as a possibility in patients with voice complaints who do not respond to reflux or antianxiety medications. Finally, a large percentage of patients, almost 25% of patients had a secondary dystonia. Investigating whether a patient with voice complaints has a dystonia can alert clinicians to patients with a higher likelihood of having SD. Although it is easy to blame these delays on physicians, it is important to note that because no objective diagnostic criteria exist for SD, it is extremely difficult for physicians, even otolaryngologists and neurologists, to provide definitive diagnosis. The current diagnostic criteria are subjective and based on individual practitioners interpretation of examination findings. We believe these results underscore the fact that objective criteria and procedures for diagnosis of SD are greatly needed to improve diagnostic delays in SD. There are multiple results from this study, but we believe that they all add to the small and growing fund of knowledge on the epidemiology and natural history of SD, which has been designated as a priority in SD research. 1 Furthermore, we believe that our results elucidating the delays in diagnosis of SD shed light onto an ongoing dilemma for both patients and physicians alike. Objective criteria for the diagnosis of SD and increased clinician education are greatly needed to address this diagnostic delay. This research was supported in part by NIH Grant # NS065701. 1. Ludlow CL, Adler CH, Berke GS, et al. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008; 139:495 505. Review. [PubMed: 18922334]

Creighton et al. Page 5 2. Schweinfurth JM, Billante M, Courey MS. Risk factors and demographics in patients with spasmodic dysphonia. Laryngoscope. 2002; 112:220 223. [PubMed: 11889373] 3. Sharma N, Franco RA Jr. Consideration of genetic contributions to the risk for spasmodic dysphonia. Otolaryngol Head Neck Surg. 2011; 14:369 370. [PubMed: 21636841] 4. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007; 13:411 416. [PubMed: 17442609] 5. Stacy M. Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin. 2008; 26(suppl 1):23 42. Review. [PubMed: 18603166]

Creighton et al. Page 6 FIGURE 1. Medications other than Botox prescribed to treat patient s SD symptoms.

Creighton et al. Page 7 FIGURE 2. Alternative treatments tried by SD patients to alleviate symptoms.